MedTrace Logo

HI-CHART:Feasibility of High-Dose Accelerated Conformal Radiotherapy

NCT00181506 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2009-06-30

No results posted yet for this study

Summary

In this study we try to increase the radiation dose, while reducing or keeping the radiation schedule below 4 weeks.

The study hypothesis is that it is feasible to administer hyperfractionated accelerated radiotherapy to patients with inoperable or locally advanced non small cell lung cancer.

Conditions

  • Non-Small-Cell Lung Carcinoma

Interventions

PROCEDURE

dose escalation (radiotherapy treatment schedule)

Sponsors & Collaborators

  • Maastricht Radiation Oncology

    lead OTHER

Principal Investigators

  • Rinus Wanders, MD · Maastricht Radiation Oncology (MAASTRO clinic)

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-12-31
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00181506 on ClinicalTrials.gov